Evidence Hub

In silico evaluation of quinoline-4-carboxamides as potential antimalarial agents

Mehnaz Hossain Meem, Mansour H. Almatarneh, Sahar Abdalla, Ismat Ruh Jahan, Tafsir Karim, Siam Siraji, Raymond A. Poirier, Kabir M. Uddin

Arabian Journal of Chemistry, 2026

Abstract

Malaria, caused by Plasmodium falciparum , remains a major global health challenge, exacerbated by increasing resistance to frontline therapies. This computational study evaluated 43 quinoline-4-carboxamide derivatives ( 1-43 ) against validated P. falciparum and human off-target proteins. Molecular docking identified ligand 24 as the most potent inhibitor of P. falciparum aminopeptidase N (3EBH; −10.3 kcal mol⁻ 1 ), outperforming chloroquine and quinine (−8.3 kcal mol⁻ 1 ). Ligand 24 complied with Lipinski and Veber drug-likeness rules, exhibited favorable ADMET (absorption, distribution, metabolism, excretion, toxicity) properties (clogP = 2.3, TPSA = 92 Å 2 , hERG pIC₅₀ = 0.79), and showed no predicted toxicity alerts. Molecular-dynamics simulations (20 ns) across 300-320 K confirmed stable interactions within the 3EBH-ligand 24 complex, with optimal stability at 310 K (root mean square deviation-RMSD <0.3 nm). Principal-component analysis (PCA) further indicated reliable conformational sampling (PC1 variance 60.8%, cosine content 0.36). Comparative profiling established ligand 24 as the leading candidate, integrating strong binding affinity with favorable pharmacokinetic and safety profiles. Ligand 7 also displayed promising electronic features. These findings collectively designate ligand 24 as a priority scaffold for experimental validation toward developing novel antimalarial therapeutics.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free